Assessment of QTc-interval Prolonging Medication Utilization and Associated Potential Drug-Drug Interactions in Hospitalized Cardiac Patients: A Cross-Sectional Study in Cardiology
DOI:
https://doi.org/10.35516/jjps.v17i3.2136Keywords:
QTc-interval prolonging drugs, Polypharmacy, Torsade de pointes, Potential drug-drug interaction, cardiovascular diseases, PakistanAbstract
Background: Several medications are linked to QTc-interval prolongation and torsades de pointes (TdP), a risk that is more common among hospitalized patients due to polypharmacy and associated QTc-interval-prolonging drug-drug interactions (QTc-pDDIs).
Objective: This study aimed to identify the prevalence of QTc-interval-prolonging drug (QTc-Drug) utilization and QTc-pDDIs among postoperative cardiac patients admitted to the National Institute of Cardiovascular Diseases (NICVD).
Method: We conducted a cross-sectional study at the NICVD, reviewing patients' medication charts for the use of QTc-Drugs and QTc-pDDIs. The CredibleMeds list was used to identify drugs associated with QTc-interval prolongation, while Micromedex Drug-Int.® and Lexicomp Interact® were utilized to screen for QTc-pDDIs.
Results: A total of 384 patients, with an average age of 48.9 ± 13.9 years, were included in the study. On average, patients used 10.3 ± 1.7 medications. Of the 3,956 medications prescribed, 22.9% were QTc-Drugs. The most frequently used QTc-Drug classes were diuretics (69.3%), anti-emetics (61.5%), and proton pump inhibitors (51.0%). Overall, 99.7% of patients received at least one QTc-Drug. The most frequent QTc-pDDI was ciprofloxacin-domperidone (7.6%), classified as major by Micromedex and a category B interaction by Lexicomp.
Conclusion: The prevalence of QTc-Drugs was very high among postoperative cardiac patients, with nearly all patients (99.7%) receiving at least one QTc-Drug. The most common QTc-pDDI was ciprofloxacin-domperidone (7.6%), identified as a major interaction by Micromedex and a category B interaction by Lexicomp. Category X (contraindicated) QTc-pDDIs should be avoided in hospitalized patients.
References
Humza, A.U., Rizvi, Kashif, Ali, Kashif, Incorporation of Pharmacist in Conducting Medication Reviews for Identification of Risk of QT Prolongation: A Neglecting Latent Approach in Cardiology. Journal of Pharmaceutical Care. 2022;10(3):175-179.
Al Meslamani, A.Z., et al., Assessment of inappropriate prescribing of QT interval-prolonging drugs in end-stage renal disease patients in Jordan. Drugs Therapy Perspectives. 2021;37:87-93. DOI: https://doi.org/10.1007/s40267-020-00806-x
Fernandes, F.M., et al., QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS One. 2018;13(6):1-12. DOI: https://doi.org/10.1371/journal.pone.0199028
Khan, Q., M. Ismail, and I. Haider, High prevalence of the risk factors for QT interval prolongation and associated drug–drug interactions in coronary care units. Postgraduate medicine. 2018; 130(8):660-665. DOI: https://doi.org/10.1080/00325481.2018.1516106
Sheikh-Taha, M. and M. Asmar, Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC geriatrics. 2021; 21: 1-6. DOI: https://doi.org/10.1186/s12877-021-02183-0
Allen LaPointe, N.M., et al., Frequency of high‐risk use of QT‐prolonging medications. Pharmacoepidemiology drug safety. 2006; 15(6):361-368. DOI: https://doi.org/10.1002/pds.1155
Smithburger, P.L., et al., QT prolongation in the intensive care unit: commonly used medications and the impact of drug–drug interactions. Expert Opinion on Drug Safety. 2010; 9(5):699-712. DOI: https://doi.org/10.1517/14740331003739188
Gorard, D.A., Escalating polypharmacy. Journal of the Association of Physicians. 2006; 99(11):797-800. DOI: https://doi.org/10.1093/qjmed/hcl109
Hsien, L. and S. Srour, Potential Drug-Drug Interactions and their Associated Factors at the University Children's Hospital in Syria: A Cross-Sectional Study. Jordan Journal of Pharmaceutical Sciences. 2024;17(1):187-198. DOI: https://doi.org/10.35516/jjps.v17i1.1606
Armahizer, M.J., et al., Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. Journal of critical care. 2013; 28(3):243-249. DOI: https://doi.org/10.1016/j.jcrc.2012.10.014
Das, B., et al., Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapies. 2019; 74(6):599-609. DOI: https://doi.org/10.1016/j.therap.2019.03.008
Dhanani, T.C., E.H. Mantovani, and J.R. Turner, Clinical pharmacists' opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to action. International Journal of Pharmacy Practice. 2017; 25(2):176-179. DOI: https://doi.org/10.1111/ijpp.12303
Tisdale, J.E., et al., Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circulation: Cardiovascular Quality Outcomes. 2013; 6(4): 479-487. DOI: https://doi.org/10.1161/CIRCOUTCOMES.113.000152
Vandael, E., et al., Development of a risk score for QTc-prolongation: the RISQ-PATH study. International Journal of Clinical Pharmacy. 2017; 39:424-432. DOI: https://doi.org/10.1007/s11096-017-0446-2
Smithburger, P.L., S.L. Kane-Gill, and A.L. Seybert, Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug safety. 2010; 33:879-888. DOI: https://doi.org/10.2165/11532340-000000000-00000
Daniel, W.W. Biostatistics: a foundation for analysis in the health sciences. 1978: Wiley.
Kheshti, R., M. Aalipour, and S. Namazi, A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. Journal of research in pharmacy practice. 2016; 5(4):257-263. DOI: https://doi.org/10.4103/2279-042X.192461
Khan, Q., et al., Prevalence of the risk factors for QT prolongation and associated drug–drug interactions in a cohort of medical inpatients. Journal of the Formosan Medical Association, 2019; 118(1):109-115. DOI: https://doi.org/10.1016/j.jfma.2018.01.016
Humza, A.U., Hameed, A., Akbar, M.A., Ahmed, I., Ali, A., Yousuf, J.B, Evaluation of medication use and polypharmacy in postoperative cardiac patients: The clinical pharmacist's imperative in a public institute of Pakistan. Pakistan Journal of Pharmaceutical Sciences, 2024; 37(1):17-23.
Wiśniowska, B. and S. Polak, The role of interaction model in simulation of drug interactions and QT prolongation. Current Pharmacology Reports. 2016; 2:339-344. DOI: https://doi.org/10.1007/s40495-016-0075-9
Pasquier, M., et al., Prevalence and determinants of QT interval prolongation in medical inpatients. Internal Medicine Journal. 2012; 42(8):933-940. DOI: https://doi.org/10.1111/j.1445-5994.2011.02447.x
Etchegoyen, C.V., et al., Drug-induced QT interval prolongation in the intensive care unit. Current Clinical Pharmacology. 2017. 12(4):210-222. DOI: https://doi.org/10.2174/1574884713666180223123947
Khan, Q., et al., QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study. European Journal of Clinical Pharmacology. 2017; 73:1511-1518. DOI: https://doi.org/10.1007/s00228-017-2321-4
Nusair, M., et al., Pharmacy students’ attitudes to provide rational pharmaceutical care: A multi-institutional study in Jordan. Jordan Journal of Pharmaceutical Sciences, 2021; 14(1).
Drew, B.J., Prevention of torsade de pointes in hospital settings: a scientific statement From the American Heart Association and the American College of Cardiology Foundation (vol 121, pg 1047, 2010). Circulation. 2010; 122(8):E440-E440. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192704
Amara, N., A.Y. Naser, and T. Esra’O, Patient satisfaction with pharmaceutical services in Jordan: A cross-sectional study. Jordan Journal of Pharmaceutical Sciences. 2023; 16(1):1-10. DOI: https://doi.org/10.35516/jjps.v16i1.1030
Woosley, R.L., et al., CredibleMeds. org: what does it offer? Trends in cardiovascular medicine. 2018; 28(2):94-99. DOI: https://doi.org/10.1016/j.tcm.2017.07.010
Downloads
Published
How to Cite
Issue
Section
